Tomao S, Mozzicafreddo A, Raffaele M, Romiti A, Papò M A, Campisi C
Istituto Nazionale per la ricerca sul cancro, Policlinico Umberto I di Roma.
Clin Ter. 1995 Aug-Sep;146(8-9):491-502.
Belonging to the vast family of cytokines, interferons (IFN) have recently been widely investigated concerning their possible clinical applications, both in virology and oncology. In this field results have been quite mixed but definitely encouraging. The best achievements have been obtained in hematology, and particularly in the treatment of hairy cell leukemia and chronic myelogenous leukemia, but new perspectives have also opened in the therapy of solid tumors, especially in the local treatment of superficial bladder cancer and ovarian cancer, AIDS-related Kaposi's sarcoma and malignant melanoma. IFN have in certain cases showed an efficacy comparable to that of classic treatments but with lower toxicity, and in some tumors they have even improved the results obtained so far, especially in combined therapy. We have here gathered the most recent results concerning the use of IFN in the therapy of solid tumors in order to highlight the new therapeutic opportunities available to clinical oncology.
干扰素（IFN）属于庞大的细胞因子家族，最近在病毒学和肿瘤学领域，人们对其可能的临床应用进行了广泛研究。在这一领域，结果喜忧参半，但无疑令人鼓舞。在血液学领域取得了最佳成果，尤其是在毛细胞白血病和慢性粒细胞白血病的治疗方面，但在实体瘤治疗中也开辟了新的前景，特别是在浅表性膀胱癌和卵巢癌的局部治疗、艾滋病相关的卡波西肉瘤和恶性黑色素瘤方面。在某些情况下，干扰素显示出与传统治疗相当的疗效，但毒性较低，在一些肿瘤中，它们甚至改善了目前已取得的治疗效果，尤其是在联合治疗中。我们在此收集了关于干扰素在实体瘤治疗中应用的最新结果，以突出临床肿瘤学可利用的新治疗机会。
